GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease.
10.4093/dmj.2012.36.4.262
- Author:
Jinmi LEE
1
;
Seok Woo HONG
;
Eun Jung RHEE
;
Won Young LEE
Author Information
1. Institute of Medical Research, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Publication Type:In Vitro ; Review
- Keywords:
Fatty acid oxidation;
Glucagon-like peptide 1;
Non-alcoholic fatty liver disease
- MeSH:
Diabetes Mellitus, Type 2;
Fatty Liver;
Glucagon-Like Peptide 1;
Glucose;
Homeostasis;
Incretins;
Insulin Resistance;
Lipogenesis;
Liver Diseases;
Receptors, Glucagon
- From:Diabetes & Metabolism Journal
2012;36(4):262-267
- CountryRepublic of Korea
- Language:English
-
Abstract:
Non-alcoholic fatty liver disease (NAFLD), one of the most common liver diseases, is caused by the disruption of hepatic lipid homeostasis. It is associated with insulin resistance as seen in type 2 diabetes mellitus. Glucagon-like peptide-1 (GLP-1) is an incretin that increases insulin sensitivity and aids glucose metabolism. In recent in vivo and in vitro studies, GLP-1 presents a novel therapeutic approach against NAFLD by increasing fatty acid oxidation, decreasing lipogenesis, and improving hepatic glucose metabolism. In this report, we provide an overview of the role and mechanism of GLP-1 in relieving NAFLD.
